There is no need to say that further research about optimized dosing regimens based on P2X7 pharmacokinetic data and P2X7 druggability becomes mandatory for explaining the duality of P2X7 in ALS and the molecular pathways that directly involve this receptor in the disease. Here, P2RX7 is linked to amyotrophic lateral sclerosis.